Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Protocol ID
LOXO-TRK-15003
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
New diagnosis
Relapse/ refractory
Relapse/ refractory
Location
NSW
Sponsor
Bayer
Links
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 21 years
International registry ID's
NCT02637687
| Study Title | A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors |
|---|---|
| Protocol ID | LOXO-TRK-15003 |
| Disease (Sub Disease) | Solid tumours |
| Diagnosis Stage | New diagnosis Relapse/ refractory |
| Location | NSW |
| Sponsor | Bayer |
| Links | https://clinicaltrials.gov/ct2/show/NCT02637687 |
| Trial Status | Open |
| Trial Open Date | 11/09/2017 |
| Sites | Sydney Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 21 years |
| International registry ID's | NCT02637687 |